human
rotavirus
repres
major
caus
sever
diarrheal
diseas
infant
young
children
limit
impact
oral
vaccin
global
estim
rotaviru
mortal
suboptim
use
oral
rehydr
justifi
need
altern
prophylact
therapeut
strategi
especi
immunocompromis
host
protect
effect
colostrumth
first
milk
produc
initi
h
parturitionar
well
document
literatur
particular
ingest
hyperimmun
bovin
colostrum
propos
altern
prevent
approach
human
rotaviru
gastroenter
although
immun
pregnant
cow
human
rotaviru
boost
releas
specif
immunoglobulin
g
bovin
colostrum
rais
regulatori
safeti
issu
studi
demonstr
convent
bovin
rotaviru
vaccin
suffici
enhanc
antihuman
rotaviru
protect
efficaci
bovin
colostrum
thu
provid
conserv
approach
produc
hyperimmun
bovin
colostrum
make
exploit
function
food
viral
gastroenter
repres
signific
econom
public
health
burden
caus
high
morbid
mortal
rate
mainli
poorest
countri
da
et
al
human
rotavirus
hrov
major
caus
sever
diarrheal
diseas
infant
young
children
second
common
caus
death
children
less
year
old
marcott
specif
antivir
drug
avail
convent
treatment
hrov
acut
gastroenter
larg
symptomat
involv
fluid
electrolyt
replac
mainten
nutrit
despit
introduct
oral
hrov
vaccin
significantli
reduc
incid
diseas
develop
countri
payn
et
al
impact
activ
prophylaxi
global
estim
hrov
mortal
limit
tate
et
al
mainli
due
inadequ
immun
coverag
lower
incom
countri
burden
diarrheal
diseas
higher
vaccin
mostli
need
fact
oral
vaccin
less
immunogen
given
infant
lowincom
countri
compar
highincom
countri
number
reason
includ
transplacent
matern
acquir
antibodi
breastfeed
histo
blood
group
antigen
malnutrit
microbiota
dysbiosi
environment
enteropathi
moreov
scarc
avail
vaccin
area
along
contraind
immunodefici
patient
babji
kang
binder
et
al
gaspar
et
al
glass
et
al
leav
onethird
onehalf
children
unprotect
sever
hrov
diseas
babji
kang
hindranc
togeth
suboptim
use
therapeut
oral
rehydr
solut
justifi
develop
effect
altern
prophylact
therapeut
approach
prevent
control
hrov
gastroenter
diseas
especi
immunocompromis
host
colostrum
first
milk
produc
mammari
gland
initi
h
parturit
tokuyama
et
al
stelwagen
et
al
repres
uniqu
sourc
highli
concentr
nutrit
compon
maci
growth
factor
pakkanen
aalto
gastrointestin
develop
mammalian
newborn
importantli
colostrum
provid
neonat
essenti
passiv
immun
infecti
diseas
ogra
ogra
morri
et
al
majumdar
ghose
stephan
et
al
tokuyama
et
al
ebina
et
al
cohen
stelwagen
et
al
particular
bovin
colostrum
bc
evolv
highli
effect
host
defens
mechan
rainard
riollet
rumin
transplacent
exchang
immun
factor
occur
utero
therefor
colostrum
lesser
extent
matur
milk
provid
protect
high
immunoglobulin
content
without
newborn
would
surviv
larson
et
al
immunoglobulin
present
bc
igg
igg
iga
igm
ogra
ogra
abund
differ
immunoglobulin
class
colostrum
milk
vari
among
speci
iga
predomin
human
mammari
secret
contrast
bc
igg
repres
barrington
et
al
wherea
iga
igm
present
much
lower
concentr
bc
immunoglobulin
conjunct
abil
rumin
neonat
gut
allow
unrestrict
passag
larg
immunoglobulin
molecul
provid
young
anim
passiv
immun
bush
staley
moor
et
al
although
effect
colostrum
speciesspecif
grow
bodi
literatur
document
protect
effect
bc
sever
viral
infect
human
bojsen
et
al
ng
et
al
benson
et
al
inagaki
et
al
elfakharani
et
al
particular
vaccin
cow
specif
human
pathogen
result
polyclon
pathogenspecif
antibodi
bc
antibodi
purifi
hyperimmun
bc
hbc
exploit
treatment
varieti
gastrointestin
infect
caus
pathogen
bacteria
playford
et
al
kelli
weiner
struff
sprott
virus
korhonen
et
al
mehra
inagaki
et
al
inagaki
et
al
ng
et
al
byakwaga
et
al
kramski
et
al
b
indic
hbc
could
altern
sourc
lowcost
virusspecif
antibodi
evid
togeth
high
content
antimicrobi
peptid
protein
eg
lactoferrin
lactoperoxidas
lysozym
stimul
innat
antivir
pathway
adapt
immun
respons
thapa
smolenski
et
al
stelwagen
et
al
suggest
bc
could
exploit
function
food
protect
viral
infect
consist
ingest
hbc
propos
altern
prophylact
approach
hrov
gastroenter
ebina
et
al
sarker
et
al
date
hbc
contain
hrovspecif
neutral
igg
produc
immun
pregnant
cow
hrov
harvest
colostrum
deliveri
howev
addit
cost
regulatori
safeti
issu
aris
use
hrov
vaccin
make
imposs
gener
hbc
larg
scale
altern
use
bc
nonimmun
cow
nhbc
may
bypass
limit
expect
literatur
shown
nhbc
significantli
lower
antihrov
efficaci
inagaki
et
al
studi
present
proofofconcept
data
show
protect
effect
hbc
cow
vaccin
convent
bovin
rotaviru
strain
brov
differ
hrov
genotyp
laemmli
buffer
molecular
mass
standard
electrophoresi
apparatu
onedimension
electrophoresi
suppli
biorad
laboratori
inc
hercul
ca
dithiothreitol
acetonitril
sd
iodoacetamid
formic
acid
chemic
use
experiment
work
product
pure
analyt
grade
purchas
sigmaaldrich
corp
st
loui
mo
water
acetonitril
optima
lcm
grade
liquid
chromatographym
analys
purchas
fisher
scientif
loughborough
uk
fresh
bc
hbc
sampl
suppli
advanc
medicin
aim
bologna
itali
accord
supplier
colostrum
collect
unvaccin
vaccin
pregnant
dairi
holstein
cow
three
cow
immun
subcutan
inocul
inactiv
trival
vaccin
trivacton
merial
italia
spa
milan
itali
maintain
maximum
rate
antibodi
colostr
secret
escherichia
coli
rotaviru
coronaviru
impli
develop
neonat
diarrhea
vaccin
perform
schedul
administ
mo
wk
parturit
respect
colostrum
vaccin
cow
collect
h
birth
pool
immedi
frozen
concentr
igg
whole
colostrum
sampl
mgml
protein
content
assess
previous
describ
method
sacerdot
et
al
suitabl
dilut
deminer
water
volum
suspens
introduc
steril
beaker
control
continu
stir
heat
h
suspens
skim
remov
fatti
layer
use
steril
spatula
casein
remov
adjust
ph
isoelectr
point
ph
hcl
h
product
centrifug
g
min
ensur
remov
casein
weight
compon
includ
salt
lactos
remov
use
hollowfib
crossflow
filtrat
cartridg
ge
healthcar
bioscienc
corp
westborough
nomin
molecular
weight
cutoff
coupl
tangenti
flow
filtrat
system
equip
peristalt
pump
essenti
keep
flow
recircul
continu
kross
flotangenti
flow
filtrat
system
research
iii
spectrum
laboratori
inc
rancho
dominguez
ca
ph
retent
adjust
naoh
neutral
sampl
centrifug
g
min
supernat
retain
next
step
consist
clarif
filter
follow
lyophil
affin
chromatographi
immunoglobulin
g
purifi
affin
chromatographi
use
protein
g
streptococci
stationari
phase
immobil
prepar
chromatograph
column
detail
affin
column
prepar
pack
ml
protein
g
sepharos
fast
flow
resin
ge
healthcar
chicago
il
hiscal
column
support
ge
healthcar
connect
fast
protein
liquid
chromatographi
fplc
system
plu
ge
healthcar
chromatograph
purif
start
elut
column
volum
chromatograph
bed
volum
buffer
bind
buffer
mm
sodium
phosphat
ph
sampl
load
flow
rate
ml
min
eluat
monitor
uv
detector
nm
conduct
meter
mscm
ph
meter
fraction
character
signific
uv
absorpt
automat
collect
iggdeplet
fraction
subsequ
step
consist
recov
igg
fraction
iggenrich
fraction
elut
column
elut
buffer
glycin
hydrochlorid
ph
column
regener
carri
elut
volum
chromatograph
bed
volum
ethanol
tangenti
flow
filtrat
iggenrich
iggdeplet
fraction
obtain
mix
subject
concentr
desalt
use
hollowfib
crossflow
filtrat
cartridg
nomin
molecular
weight
cutoff
surfac
area
cm
ge
healthcar
coupl
tangenti
flow
filtrat
system
equip
peristalt
pump
essenti
keep
flow
recircul
continu
kross
flotangenti
flow
filtrat
system
research
iii
iggenrich
iggdeplet
fraction
concentr
time
dialyz
volum
water
filter
membran
steril
condit
final
lyophil
onedimension
sdspage
protein
separ
perform
reduc
condit
aliquot
sampl
contain
protein
mix
laemmli
sampl
buffer
contain
mm
dithiothreitol
heat
min
sampl
standard
protein
mixtur
precis
plu
protein
standard
biorad
laboratori
inc
load
precast
gel
kd
mini
protean
tgx
biorad
laboratori
inc
place
electrophoresi
cell
miniprotean
tetra
run
v
constant
min
stain
carri
use
coomassi
blue
stain
biosaf
stain
biorad
laboratori
inc
imag
acquir
use
biorad
densitomet
analyz
use
softwar
quantiti
one
biorad
laboratori
inc
igg
content
iggenrich
iggdeplet
fraction
determin
size
exclus
chromatographi
sec
accord
method
report
altomar
et
al
sec
perform
thermo
finnigan
surveyor
hplc
system
thermofinnigan
italia
milan
itali
equip
variabl
wavelength
detector
autosampl
control
xcalibur
softwar
version
thermo
fisher
scientif
rodano
itali
sec
separ
perform
phenomenex
yarra
column
phenomenex
inc
torranc
ca
mm
precolumn
phenomenex
inc
run
isocrat
flow
mobil
phase
contain
sodium
phosphat
bibas
sodium
azid
ph
constant
flow
rate
mlmin
autosampl
temperatur
set
uv
detect
conduct
wavelength
nm
typic
wavelength
protein
detect
dipeptid
tyrosinehistidin
th
chosen
intern
standard
mark
race
front
smallest
analyt
sampl
previous
spike
small
amount
th
order
obtain
final
concentr
mm
african
green
monkey
kidney
epitheli
cell
human
epitheli
adenocarcinoma
hela
cell
atcc
propag
dulbecco
modifi
eagl
medium
dmem
gibcobrl
gaithersburg
md
supplement
heatinactiv
fetal
bovin
serum
gibcobrl
antibioticantimycot
solut
zell
shield
minerva
biolab
gmbh
berlin
germani
atmospher
co
african
green
monkey
kidney
cell
vero
cell
atcc
grown
monolay
eagl
minim
essenti
medium
gibcobrl
supplement
fetal
bovin
serum
antibioticantimycot
solut
hrov
strain
wa
atcc
atcc
atcc
brov
strain
ncdv
atcc
activ
porcin
pancreat
trypsin
type
ix
sigmaaldrich
co
min
propag
cell
use
dmem
contain
trypsin
per
ml
describ
previous
civra
et
al
viral
titer
express
focusform
unit
ffu
per
millilit
serolog
character
rotavirus
exploit
studi
provid
tabl
human
rhinoviru
hrhv
atcc
propag
hela
cell
humidifi
co
incub
clinic
isol
human
herp
simplex
viru
type
type
provid
pistello
univers
pisa
itali
human
cytomegaloviru
hcmv
strain
town
provid
w
brune
heinrich
pett
institut
hamburg
germani
vesicular
stomat
viru
vsv
atcc
hcmv
propag
vero
cell
humidifi
co
incub
full
cytopath
effect
develop
cell
supernat
harvest
pool
frozen
thaw
time
clarifi
aliquot
virus
store
viral
titer
determin
standard
plaqu
method
describ
previous
civra
et
al
cagno
et
al
express
plaqueform
unit
per
millilit
pfuml
antivir
activ
nhbc
hbc
igg
hrov
wa
ncdv
determin
focu
reduct
assay
plaqu
reduct
assay
assay
inhibit
rotaviru
infect
carri
confluent
cell
monolay
plate
tray
describ
elsewher
civra
et
al
cell
treat
h
serial
dilut
colostrum
protein
concentr
rang
proteinml
serumfre
medium
viru
addit
infect
hrov
perform
multipl
infect
moi
ffuml
h
presenc
colostrum
infect
cell
wash
serumfre
medium
fresh
methanol
extract
ad
cell
incub
medium
humidifi
incub
volvol
co
volvol
air
h
incub
infect
cell
fix
cold
acetonemethanol
viral
titer
determin
indirect
immunostain
use
mous
monoclon
antibodi
direct
human
rotaviru
covalab
villeurbann
franc
secondari
antibodi
peroxidaseconjug
affinipur
f
fragment
goat
antimous
igg
h
l
jackson
immunoresearch
laboratori
inc
west
grove
pa
plaqu
reduct
assay
hela
vero
cell
first
seed
cellswel
plate
twentyfour
hour
later
hbc
nhbc
igg
serial
dilut
medium
proteinml
ad
cell
monolay
h
incub
co
medium
remov
infect
perform
hrhv
vsv
hcmv
moi
pfuml
presenc
colostrum
infect
cell
incub
hrhv
infect
virus
h
wash
medium
overlaid
combin
seaplaqu
agaros
dmem
contain
colostrum
control
well
infect
prepar
treat
cell
equal
volum
cultur
medium
plate
incub
incub
plate
fix
formaldehyd
fluka
bucharest
romania
stain
crystal
violet
sigmaaldrich
co
number
plaqu
form
count
immunoglobulin
g
precipit
ammonium
sulfat
ad
effect
concentr
ec
ffuml
trypsinactiv
rov
suspens
mix
total
volum
untreat
neg
control
perform
equal
volum
cultur
medium
supernat
viruscompound
mixtur
incub
h
serial
dilut
noninhibitori
concentr
test
igg
residu
viral
infect
determin
previous
describ
civra
et
al
rotaviruscel
bind
assay
perform
describ
previous
civra
et
al
trypsinactiv
rov
strain
wa
ncdv
treat
describ
neutral
assay
h
cell
wash
fresh
medium
cool
ice
rov
cool
allow
attach
cell
h
moi
ffucel
wash
cold
dmem
cell
subject
round
freezethaw
incub
min
porcin
trypsin
releas
bound
viru
lysat
clarifi
lowspe
centrifug
min
cellbound
viru
titer
determin
indirect
immunostain
cell
seed
densiti
well
plate
treat
next
day
hbc
nhbc
igg
supernat
concentr
rang
gener
doserespons
curv
control
sampl
viabil
prepar
treat
cell
cultur
medium
h
incub
cell
viabil
determin
use
celltit
prolifer
assay
kit
promega
madison
wi
follow
manufactur
instruct
absorb
measur
use
micropl
reader
model
biorad
laboratori
nm
viabil
treat
cell
express
percentag
rel
cell
incub
cultur
medium
blockad
viral
infect
express
mean
percent
standard
deviat
sd
possibl
antivir
effect
concentr
ec
valu
calcul
regress
analysi
use
doserespons
curv
gener
experiment
data
use
prism
graphpad
softwar
san
diego
ca
cytotox
concentr
cc
determin
use
logarithm
viabil
curv
possibl
select
index
si
calcul
divid
cc
ec
oneway
anova
follow
bonferroni
test
use
assess
statist
signific
differ
treat
untreat
sampl
ec
valu
compar
use
sumofsquar
f
test
signific
set
level
figur
display
sdspage
profil
colostrum
protein
reduc
condit
rel
follow
sampl
colostrum
nonimmun
lane
immun
lane
cow
correspond
defat
caseindeplet
dialyz
filter
sampl
lane
expect
protein
profil
show
intens
band
approxim
kda
repres
heavi
light
igg
chain
respect
band
repres
classic
set
highabund
speci
normal
found
milk
anim
origin
although
colostrum
igg
alon
repres
total
protein
mass
includ
kda
kda
serum
transferrin
kda
kda
expect
protein
pattern
rel
colostrum
sampl
differ
respect
correspond
defat
caseindeplet
dialyz
filter
sampl
signific
reduct
band
attribut
casein
lane
figur
purif
igg
colostrum
collect
nonimmun
immun
cow
achiev
use
prepar
affin
chromatographi
system
base
protein
g
streptococci
highli
select
bovin
igg
affin
chromatogram
trace
record
nm
display
peak
first
retain
correspond
nonimmunoglobulin
protein
fraction
second
igg
fraction
figur
peak
account
electrophoret
pattern
obtain
collect
fraction
figur
indic
good
deplet
immunoglobulin
whose
characterist
band
kda
weak
aliquot
elut
within
first
peak
much
intens
fraction
second
peak
correspond
immunoglobulin
secuv
method
optim
achiev
reproduc
separ
abund
analyt
bovin
colostrum
method
appli
verifi
puriti
fraction
obtain
nonimmunoglobulin
protein
fraction
igg
elut
fraction
figur
repres
typic
chromatogram
record
set
uv
detector
nm
rel
iggdeplet
figur
iggenrich
figur
fraction
spike
intern
standard
th
mm
typic
retent
time
igg
dipeptid
th
min
respect
peak
rel
igg
evid
iggenrich
fraction
absent
iggdeplet
fraction
character
peak
repres
igm
biochem
character
colostrum
igg
sampl
test
antivir
activ
result
summar
tabl
show
neither
nhbc
hbc
antivir
activ
human
pathogen
includ
hcmv
hrhv
although
hbc
show
weak
antivir
activ
nevertheless
abl
inhibit
viral
infect
expect
nhbc
effect
bovin
pathogen
brov
ncdv
ec
proteinml
vsv
ec
protein
ml
tabl
note
nhbc
nonstrainrestrict
antivir
efficaci
hrov
strain
wa
ec
proteinml
ec
proteinml
ec
protein
ml
percentag
inhibit
figur
test
hypothesi
colostrum
cow
immun
veterinari
antibrov
vaccin
may
exert
higher
antihrov
activ
nonimmun
cow
perform
second
set
antivir
assay
expect
hbc
exert
significantli
p
f
test
higher
antivir
activ
brov
ncdv
ec
proteinml
compar
colostrum
nonimmun
cow
tabl
result
indic
vaccin
elicit
antibrov
immun
respons
notabl
hbc
also
significantli
p
f
test
effect
nhbc
wa
ec
proteinml
ec
proteinml
ec
proteinml
tabl
suggest
high
titer
crossreact
igg
hbc
therefor
perform
third
set
experi
test
presenc
antihrov
igg
hbcderiv
igg
result
shown
tabl
figur
demonstr
igg
inhibit
infect
brov
strain
ncdv
ec
proteinml
interestingli
also
strong
antivir
activ
hrov
strain
wa
ec
proteinml
ec
proteinml
ec
proteinml
percentag
inhibit
neg
control
igg
antivir
assay
treat
cell
equal
volum
iggdeplet
supernat
result
shown
tabl
figur
show
iggdeplet
supernat
signific
antivir
activ
notabl
treatment
differ
cell
line
nhbc
hbc
igg
affect
cell
viabil
even
high
concentr
show
antivir
activ
observ
caus
nonspecif
cytotox
effect
mechan
action
experi
show
igg
neutral
viru
infect
significantli
p
anova
inhibit
rovcel
bind
figur
b
c
importantli
signific
p
anova
neutral
viral
infect
observ
viru
inactiv
assay
figur
e
f
consist
neutral
activ
virusspecif
antibodi
target
rov
surfac
antigen
rather
cellular
receptor
support
properti
bc
consum
mammalian
speci
includ
pig
human
well
document
medic
literatur
bridger
brown
pakkanen
aalto
gopal
gill
et
al
solomon
uruakpa
et
al
boudri
et
al
struff
sprott
emerg
evid
indic
bc
promis
nutraceut
could
prevent
mitig
variou
diseas
newborn
adult
bagw
et
al
particular
gastrointestin
infect
consist
find
studi
confirm
protect
activ
nhbc
hrov
well
document
literatur
inagaki
et
al
inagaki
et
al
note
nhbc
also
show
antivir
activ
sever
hrov
strain
expect
brov
strain
ncdv
concentr
compar
previous
shown
inagaki
et
al
experiment
set
nhbc
show
signific
antivir
activ
viral
pathogen
name
hrhv
hcmv
result
show
bc
broadspectrum
antivir
rather
exert
specif
antivir
activ
like
antivir
specif
potenc
reflect
immunolog
statu
anim
boost
natur
concentr
immun
compon
colostrum
milk
vaccin
cow
offer
great
potenti
use
prophylact
therapeut
product
human
hyperimmun
bc
cow
vaccin
hrov
effect
therapeut
approach
reduc
durat
sever
rovcaus
diarrhea
doubleblind
control
clinic
studi
infant
mo
age
mitra
et
al
second
studi
davidson
et
al
produc
hbc
introduc
vaccin
contain
hrov
pregnant
friesian
cow
demonstr
hbc
administ
oral
mediat
protect
prevent
hrov
infect
efficaci
passiv
immun
hbcderiv
igg
document
literatur
hilpert
et
al
treat
infant
hospit
acut
diarrhea
antirotaviru
immunoglobulin
concentr
without
observ
signific
decreas
durat
diarrhea
excret
viru
turner
kelsey
demonstr
reduct
incid
durat
diarrhea
treat
infant
sarker
et
al
produc
hbc
immun
pregnant
cow
hrov
strain
wa
repres
serotyp
respect
hbcpurifi
igg
administ
doubleblind
placebocontrol
trial
children
diagnos
hrov
diarrhea
children
receiv
hbcigg
significantli
less
daili
total
stool
output
frequenc
requir
less
oral
rehydr
solut
children
receiv
placebo
howev
difficult
gener
largescal
amount
hbc
immun
cow
unconvent
hrov
vaccin
inde
yield
insuffici
cover
global
requir
death
occur
worldwid
everi
year
due
rotavirusinduc
diarrhea
bagw
et
al
overcom
limit
propos
test
hypothesi
hbc
cow
immun
convent
veterinari
vaccin
brov
would
exert
higher
antihrov
activ
nhbc
due
high
titer
crossreact
antihrov
igg
inde
result
confirm
hypothesi
indic
easier
cheaper
approach
product
antihrov
hbc
igg
cow
demonstr
vitro
hrov
inhibit
efficaci
ie
ec
hbc
compar
inagaki
colleagu
treat
cell
skim
concentr
bovin
late
colostrum
hrovimmun
cow
inagaki
et
al
inagaki
et
al
demonstr
hbc
igg
inhibit
infect
rov
differ
figur
mechan
action
hyperimmun
bovin
colostrum
hbc
deriv
igg
untreat
colostrum
ammonium
sulfat
supernat
rotaviru
strain
panel
b
c
show
effect
hbcderiv
igg
wa
ncdv
respect
bind
cell
surfac
panel
e
f
show
result
viru
inactiv
assay
infecti
particl
wa
ncdv
respect
yaxi
infecti
titer
hrov
express
focusform
unit
per
millilit
ffuml
error
bar
repres
sem
independ
experi
p
p
p
hrov
human
rotaviru
brov
bovin
rotaviru
gp
genotyp
tabl
suggest
vaccin
brov
stimul
product
crossreact
neutral
antibodi
view
exploit
hbc
sourc
antihrov
igg
qualiti
assess
procedur
necessari
monitor
igg
content
nevertheless
techniqu
alreadi
avail
well
document
literatur
altomar
et
al
moreov
cow
produc
bc
larg
excess
respect
amount
need
feed
calv
cow
produc
l
colostrum
day
first
day
parturit
ld
administ
calf
first
deverypociu
larson
overal
demonstr
convent
brov
vaccin
suffici
boost
antihrov
protect
efficaci
bc
repres
conserv
feasibl
yieldlimit
approach
produc
hbc
could
exploit
function
food
prevent
treat
hrov
infect
